Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity

Antiviral Therapy

Volumn 15, Issue 4, 2010, Pages 579-586

  Martin, Mélanie ^a   Azzi, Arezki ^b   Lin, Sheng Xiang ^b   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FOSCARNET; GANCICLOVIR; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CYTOMEGALOVIRUS; ENZYME ACTIVITY; ENZYME STABILITY; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE LYSATE; THERMOSTABILITY; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; GENETIC RECOMBINATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PHYSIOLOGY; PROCEDURES; RABBIT; RETICULOCYTE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FIBROBLASTS; FOSCARNET; GANCICLOVIR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; RABBITS; RECOMBINATION, GENETIC; RETICULOCYTES; VIRUS REPLICATION;

EID: 77956803865     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1565     Document Type: Article

References (30)

1. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30:231-233.
2. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60-65.
3. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13:83-121. (Pubitemid 30039345)
4. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1- (hydroxymethyl) ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985; 82:2473-2477.
5. Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996; 50:1502-1510.
6. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 359:85.
7. Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41:104-129. (Pubitemid 21920729)
8. Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786-789.
9. Erice A, Gil-Roda C, Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087-1092.
10. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645-649. (Pubitemid 30627592)
11. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20-27.
12. Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77.
13. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188:32-39.
14. Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998; 248:382-393.
15. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883. (Pubitemid 40327699)
16. Cihlar T, Fuller M, Cherrington J. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72:5927-5936.
17. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51:4160-4162.
18. Tchesnokov EP, Gilbert C, Boivin G, Gotte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to foscarnet. J Virol 2006; 80:1440-1450.
19. Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000; 44:688-692.
20. Cihlar T, Fuller MD, Cherrington JM. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expr Purif 1997; 11:209-218. (Pubitemid 27498910)
21. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006; 64:301-307.
22. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281:18193-18200.
23. Parthiban V, Gromiha MM, Schomburg D. CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 2006; 34:W239-W242. (Pubitemid 44529771)
24. Eriksson B, Oberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982; 696:115-123.
25. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996; 70:1390-1395.
26. Springer KL, Chou S, Li S, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43:208-213.
27. Ducancelle A, Champier G, Alain S, et al. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir Ther 2006; 11:537-540. (Pubitemid 44024862)
28. Franklin MC, Wang J, Steitz TA. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 2001; 105:657-667.
29. Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003; 77:7820-7829.
30. Andrei G, Fiten P, Froeyen M, et al. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007; 12:719-732.